Investigational drugs for coagulation disorders.

about

Biological therapies for inherited diseases: social and bioethical considerations. Hemophilia as an example.Outcome of Clinical Trials with New Extended Half-Life FVIII/IX Concentrates.

P2860

Q38397299-C018C8A8-083B-4498-9BAD-B7362E760824 Q39204747-7126A4FD-7D1C-4B56-BFFB-4D11EE83D3FA

P2860

Investigational drugs for coagulation disorders.

Item

http://www.wikidata.org/entity/Q38106245

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Investigational drugs for coagulation disorders.

@en

type

Item

label

Investigational drugs for coagulation disorders.

@en

prefLabel

Investigational drugs for coagulation disorders.

@en

P1476

Investigational drugs for coagulation disorders.

@en

P2093

Maria Elisa Mancuso

http://www.w3.org/2001/XMLSchema#string

P2860

Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients.

Purification and characterization of a new recombinant factor VIII (N8).

Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment.

Glycoengineering: the effect of glycosylation on the properties of therapeutic proteins.

Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia.

Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients

Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone

Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients.

Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity.

Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients.

P304

945-953

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/13543784.2013.798302

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Pier Mannuccio Mannucci

P577

2013-05-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23668400

http://www.w3.org/2001/XMLSchema#string

Investigational drugs for coagulation disorders.

about

P2860

P2860

Investigational drugs for coagulation disorders.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698